Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (α<sub>1</sub>-AR antagonists) may be effective in reducing mortality related to hyperinflammation independent of etiology. The gene discussed is AR; the disease is COVID-19.